Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers

References

• Weng P, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: Longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol. 2011;6(5):1121–1128.
   PubMed Web of Science ®Google Scholar
• Estakhri R, Ghahramanzade A, Vahedi A, Nourazarian A. Serum levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis. Asian Pacific J Cancer Prev. 2013;14(3):1597–1599.
   PubMedGoogle Scholar
• Coppolino G, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumor markers and kidney function: A systematic review. Biomed Res Int. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Hussain S, Abbas G. Prostate specific antigen levels in pre-dialysis chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2010;21(2):354–356.
   PubMedGoogle Scholar
• Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1238–1241.
   PubMed Web of Science ®Google Scholar
• Joseph DA, Thompson T, Saraiya M, Werny DM. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. Urology. 2010;76(5):1042–1046.
   PubMed Web of Science ®Google Scholar
• Mercadal L. Tumor markers in chronic kidney disease. Nephrol Ther. 2015;11(2):122–124.
   PubMed Web of Science ®Google Scholar
• Arik N, Adam B, Akpolat T, Has Kil, S, Tabak S. Serum tumour markers in renal failure. Int Urol Nephrol. 1996;28(4):601–604.
   PubMedGoogle Scholar
• García-Sánchez C, Corchuelo-Maillo C, Congregado-Ruiz CB, et al. PSA levels in patients on hemodialysis treatment. Arch Esp Urol. 2013;66(10):939–944.
   PubMed Web of Science ®Google Scholar
• Bruun L, BJork T, Hans L, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on hemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003;18(3):598–603.
   PubMed Web of Science ®Google Scholar
• Sumura M, Yokogi H, Beppu M, Honda H. Diagnostic value of serum prostate-specific antigen in hemodialysis patients. Int J Urol. 2003;10(5):247–250.
   PubMed Web of Science ®Google Scholar
• Khairullah QT, Pamatmat SD, Chatha M, Provenzano R, Telang D, Temple M. Early detection of prostate cancer in the ESRD population. Clin Nephrol. 2004;61(5):308–315.
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakanishi J, Takahashi W, et al. Mass screening for prostate cancer in patients with end-stage renal disease: A comparative study. BJU Intl. 2006;98(4):794–797.
   PubMed Web of Science ®Google Scholar
• Tarhan F, Orcun A, Kucukercan I, Camursoy N, Kuyumcuoglu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol. 2007;41(5):382–386.
   Web of Science ®Google Scholar
• Holley JL. Screening, diagnosis and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol. 2007;2(3):604–610.
   PubMed Web of Science ®Google Scholar
• Kleinclauss F, Gigante M, Neuzillet Y, et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant. 2008;23(7):2374–2380.
   PubMed Web of Science ®Google Scholar
• Cormier L, Lechevallier E, Barrou B, et al. Diagnosis and treatment of prostate cancers in renal transplant recipients. Transplantation. 2003;75(2):237–239.
   PubMed Web of Science ®Google Scholar
• Mahdavi R, Zeraati A, Tavakkoli M, Aghamohammadpour K, Ghoreifi A. Effect of kidney transplantation on early and late post-transplant prostate-specific antigen levels. Saudi J Kidney Dis Transpl. 2014;25(2):362–366.
   PubMedGoogle Scholar
• Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C, de Vere White RW. The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. Am J Transplant. 2008;8(12):2668–2673.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Ditonno P, Bettocchi C, et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125 and Beta-2 microglobulin in renal cell carcinoma. Dis Markers. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Engin H, Borazan A, Aydemir S, Yilmaz A. Assessment of tumor markers in patients with chronic renal failure. Turkish J Cancer. 2007;37(4):143–147.
   Google Scholar
• Tzitzikos G, Saridi M, Filippopoulou T, et al. Measurement of tumor markers in chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2010;21(1):50–53.
   PubMedGoogle Scholar
• Xiaofang Y, Yue Z, Xialian X, Zhibin Y. Serum tumor markers in patients with chronic kidney disease. Scand J Clin Lab Invest. 2007;67(6):661–667.
   PubMed Web of Science ®Google Scholar
• Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;55(5):916–922.
   PubMed Web of Science ®Google Scholar
• Malati T. Tumor markers: An overview. Indian J Clin Biochem. 2007;22(2):17–31.
   PubMedGoogle Scholar
• Zeferos N, Digenis GE, Christophoraki M, et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron. 1991;59(4):618–620.
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, Mayer G. Serum markers after renal transplantation. Transplantation. 1996;62(10):1506–1509.
   PubMed Web of Science ®Google Scholar
• Wood WG, Steinhoff J, Kessler AC. Anomalous tumor marker concentrations in renal transplant patients. Eur J Clin Chem Clin Biochem. 1993;31(2):75–82.
   PubMedGoogle Scholar
• Duffy MJ, McGing P. Guidelines for the Use of Tumor Markers. 3rd ed., Ireland: Scientific Committee of the Association of Clinical Biochemists (ACBI); 2005.
   Google Scholar
• Rao SN. Cancer screening in end-stage renal disease. Saudi J Kidney Dis Transpl. 2009;20(5):737–740.
   PubMedGoogle Scholar
• Nagy B Jr, Krasznai ZT, Balla H, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49(4):377–380.
   PubMed Web of Science ®Google Scholar
• Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA 125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013;8:11.
   PubMed Web of Science ®Google Scholar
• Simmons AR, Baggerly K, Bast Jr RC. The emerging role of HE4 in the evaluation of advanced epithelial ovarian and endometrial carcinomas. Oncology (Williston Park). 2013;27(6):548–556.
   PubMed Web of Science ®Google Scholar
• Anastasi E, Granato T, Falzarano R, et al. The use of HE4, CA 125 and CA 72-4 biomarkers or differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res. 2013;6(44):1–8.
   PubMed Web of Science ®Google Scholar
• Yontem M. Investigation of the serum levels of tumor markers in the patients chronic renal failure. Int J Sci Technol Res. 2015;1(2):115–119.
   Google Scholar
• Dieplinger H, Ankerst DP, Burges A, et al. Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1127–1133.
   PubMed Web of Science ®Google Scholar
• Dieplinger H, Dieplinger B. Afamin-A pleiotropic glycoprotein involved in various disease states. Clin Chim Acta. 2015;446:105–110.
   PubMed Web of Science ®Google Scholar
• Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics. 2010;9(9):1954–1967.
   PubMed Web of Science ®Google Scholar
• Myata T, Jadoul M, Kurokawa K, Van Yepersele De Strihou C. β2-microglobulin in renal disease. J Am Soc Nephrol. 1998;9:1723–1735.
   PubMed Web of Science ®Google Scholar
• Li K, Du H, Lian X, et al. Characterization of β2-microglobulin expression in different types of breast cancer. BMC Cancer. 2014;14:750.
   PubMed Web of Science ®Google Scholar
• Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Kaur M. β2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem. 2014;14(3):343–352.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Cohen G, Wiecek A, Jesus Carrero J. The peptidic middle molecules: Is molecular weight doing the trick? Semin Nephrol. 2014;34(2):118–134.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Patima S, Ye DX, Pan HY, Zhang P, Zhang ZY. Upregulation of β2-microglobulin expression in progressive human oral squamous cell carcinoma. Oncol Rep. 2012;27(4):1058–1064.
   PubMed Web of Science ®Google Scholar
• Blum C, Graham A, Yousefzadeh M, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. 2008;33(3):579–584.
   PubMed Web of Science ®Google Scholar
• Gross M, Top I, Laux I, et al. β-2-Microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007;13(7):1979–1986.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Cortes J, Talpaz M, et al. Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000;6:147–152.
   PubMed Web of Science ®Google Scholar
• Dajak M, Ignjatovi S, Biljana Stojimirovi B, Gaji S, Majki-Singh N. Beta-trace protein as a marker of renal dysfunction in patients with chronic kidney disease: comparison with other renal markers. J Med Biochem. 2010;29(2):66–72.
   Web of Science ®Google Scholar
• Astor BC, Muth B, Kaufman DB, Pirsch JD, Hofmann RM, Djamali A. Serum β2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney Int. 2013;84:810–817.
   PubMed Web of Science ®Google Scholar
• Zumrutdal A. Role of β2-microglobulin in uremic patients may be greater than originally suspected. World J Nephrol. 2015;4(1):98–104.
   PubMedGoogle Scholar
• Raikou VD, Kyriaki D. The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment. J Diabetes Metab Disord. 2015;14(34):1–6.
   PubMedGoogle Scholar
• Huang WC, Havel JJ, Zhau HE, et al. β2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res. 2008;14(17):5341–5347.
   PubMed Web of Science ®Google Scholar
• Soni S, Menon MC, Bhaskaran M, Jhaveri KD, Molmenti E, Muoio V. Elevated human chorionic gonadotropin levels in patients with chronic kidney disease: Case series and review of literature. Indian J Nephrol. 2013;23(6):424–427.
   PubMedGoogle Scholar
• Hayden Y, Bezuidenhout E, de Lange W, Van Schalkwyk O. Persistent elevation of BHCG-levels in a patient with stage 5D chronic kidney disease. J Endocrinol Metab Diabetes South Africa. 2015;20(1):38–46.
   Google Scholar
• Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075–1082.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Hofmann BR, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56(6):e1–e48.
   Google Scholar
• Ragab H, Abd El Maksoud N, Essam T. The impact of use serum carcinoembryonic antigen and Beta2-microglobulin in monitoring bronchogenic carcinoma therapy. J Genet Eng Biotechnol. 2007;5(1-2):43–50.
   Google Scholar
• Myers JB, Frost M, Coates AS, Mathews JD, Kincaid-Smith P. Carcinoembryonic antigen in renal allograft recipients and immunosuppressed renal patient. Aust N Z J Med. 1977;7(1):16–19.
   PubMedGoogle Scholar
• Bo L. Clinical value of serum tumor markers detection in maintenance hemodialysis patients. Chin J Clin Oncol Rehabil. 2013;3:201–203.
   Google Scholar
• Nam DI, Kang C, Jung IH, Moon HG, Youn BR, Lee NH. Pseudomembranous colitis: A complicated case with transient increase of carcinoembryonic antigen. Ewha Med J. 2015;38(1):54–58.
   Google Scholar
• Talamo G, Barochia A, Zangari M, Loughran TP. Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors. 2010;2(1):e4.
   PubMedGoogle Scholar
• d’Herbomez M, Do Cao C, Vezzosi D, Borzon-chasot F, Boudin E. Chromogranin A assay in clinical practice. Ann Endocrinol. 2010;71(4):274–280.
   PubMed Web of Science ®Google Scholar
• Kurnatowska I, Nowicki M. Serum chromogranin A concentration and intradialytic hypotension in chronic hemodialysis patients. Int Urol Nephrol. 2006;38(3-4):701–705.
   PubMed Web of Science ®Google Scholar
• Tramonti G, Ferdeghini M, Annichiarico C, et al. Relationship between renal function and blood level of chromogranin A. Ren Fail. 2001;23(3-4):449–457.
   PubMed Web of Science ®Google Scholar
• Awadallah AM, Issa HA, Soliman MS. Evaluation of serum chromogranin A as a useful tumor marker for diagnosis of hepatocellular carcinoma. J Am Sci. 2011;7(1):999–1007.
   Google Scholar
• Salem RM, Cadman PE, Chen Y, et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol. 2008;19(3):600–614.
   PubMed Web of Science ®Google Scholar
• Catania VE, Vinci E, Madeddu R, et al. Chromogranin A serum levels in elderly patients with ovarian cancer. Acta Med Mediterranea. 2014;30:1053–1057.
   Web of Science ®Google Scholar
• Wise-Draper T, Qualtieri J, Mogilishetty G, Latif T. Concurrent presentation of high-grade lymphoma and metastatic pancreatic neuroendocrine tumor 14 years after renal transplant. Hematol. 2014;3(4):112–115.
   Google Scholar
• Castoldi G, Antolini L, Bombardi C, et al. Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment. Clin Biochem. 2010;43(18):1387–1392.
   PubMed Web of Science ®Google Scholar
• Elshabrawy S, Farid A, El-Beddini M, Osman A, El-Deeb S. Evaluation of C-reactive protein as a probable factor for cancer diagnosis. Life Sci J. 2012;9(4):2796–2803.
   Web of Science ®Google Scholar
• Xiao L, Liu YP, Xiao CX, Ren JL, Guleng B. Serum TFF3 may be a pharmacodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol. 2014;14:26.
   PubMedGoogle Scholar
• Kim BC, Jung SW, Kim JB, et al. Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth? Turk J Gastrointerol. 2014;25(6):611–618.
   PubMed Web of Science ®Google Scholar
• Yu TY, Li HY, Jiang YD, et al. Serum vascular adhesion protein-1 level predicts risk of incident cancers in subjects with type II diabetes. Cancer Epidemiol Biomarkers Prev. 2014;23(7);1366–1373.
   PubMed Web of Science ®Google Scholar
• Turkmen K, Ecder T, Turk S. The relationship between serum zinc levels and tumor markers in hemodialysis patients. Eur J Gen Med. 2014;11(3):174–178.
   Google Scholar